01—Abstract
Summary
Summary of the 8-K filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.
DexCom reported second quarter 2025 results on July 30, 2025 that beat on the top line and raised full-year revenue guidance, while margin guidance was reiterated.
Revenue grew 15% year-over-year to $1.157 billiona (15% organic), with U.S. revenue up 15% and international up 16% on a reported basis. GAAP operating income rose 270 basis points to 18.4% of revenue, while non-GAAP operating margin of 19.2% declined 30 basis points year-over-year. GAAP diluted EPS was $0.45 versus $0.35 a year earlier, and non-GAAP diluted EPS was $0.48 versus $0.43.
The company ended the quarter with $2.93 billionb in cash and marketable securities and an undrawn revolver. Sensor and other revenue grew 18%, while hardware revenue declined 31%, a mix shift that supports recurring-revenue quality. The company raised 2025 revenue guidance to $4.600-$4.625 billion (14-15% growth) and reiterated non-GAAP gross margin of about 62%, non-GAAP operating margin of about 21%, and Adjusted EBITDA margin of about 30%.
The most significant item for investors is the CEO succession plan: Jacob (Jake) Leach, currently President and COO, will become President and CEO effective January 1, 2026, and will join the board. Kevin Sayer will step down as CEO on that date and become Executive Chairman. The Board also expanded to ten directors effective the same date.
No new compensation arrangements had been entered into as of filing, and the company committed to amend the 8-K if any are made. The press release also disclosed that the G7 15 Day CGM System received FDA clearance, which the company expects to launch in the second half of 2025.
Ongoing patent litigation against Abbott Diabetes Care is a continuing cost item, though intellectual property litigation costs fell sharply year-over-year, from $22.3 million to $0.2 millionc in the quarter. Investors should watch the gross margin trajectory, since GAAP gross margin compressed about 290 basis points to 59.5%, and the scheduled leadership transition.
02—Key points
Key Highlights
- Q2 2025 revenue rose 15% year-over-year to $1.157 billion, with sensor and other revenue up 18% and hardware revenue down 31%
- Full-year 2025 revenue guidance raised to $4.600-$4.625 billion (14-15% growth); non-GAAP gross margin (~62%), operating margin (~21%), and Adjusted EBITDA margin (~30%) reiterated
- GAAP operating income increased 270 bps to 18.4% of revenue, while non-GAAP operating margin declined 30 bps to 19.2%
- GAAP gross margin fell to 59.5% from 62.4% a year earlier, and non-GAAP gross margin fell to 60.1% from 63.5%
- Non-GAAP diluted EPS of $0.48 versus $0.43 a year ago; GAAP diluted EPS of $0.45 versus $0.35
- CEO succession: Jake Leach becomes President and CEO and joins the Board effective January 1, 2026; Kevin Sayer becomes Executive Chairman
- Strong balance sheet with $2.93 billion in cash, cash equivalents, and marketable securities; revolving credit facility undrawn
03—Questions
Frequently Asked Questions
Why is Dexcom changing CEOs, and what does the transition look like?
Kevin Sayer notified the Board of his intent to retire as CEO effective January 1, 2026, and will remain on as Executive Chairman to provide strategic guidance. Jake Leach, who has been President and COO and has been with the company for 21 years, will succeed him as President and CEO and join the Board. Leach will be the sole principal executive and operating officer after the transition. Sayer will work closely with Leach during the interim period.
Did Dexcom's profitability improve in Q2 2025?
It depends on the measure. GAAP operating income rose to $212.6 million from $158.0 million, and GAAP operating margin improved 270 bps to 18.4%, largely because prior-year intellectual property litigation and transition costs were much higher. Non-GAAP operating margin fell 30 bps to 19.2%, and gross margin compressed on both GAAP and non-GAAP bases, reflecting higher cost of sales relative to revenue.
Is Dexcom on track to meet its 2025 guidance?
The company raised its revenue outlook to $4.600-$4.625 billion, implying 14-15% growth, and reiterated its margin targets. First-half revenue of $2.193 billion means the second half needs to contribute roughly $2.41-$2.43 billion to reach the guided range, which is consistent with the first-half run rate. The reiterated margin guidance, however, requires the second half to recover from Q2's gross margin level.
What is the outlook for the Dexcom G7 15 Day system?
The company received FDA clearance for the G7 15 Day CGM System in the second quarter and said it looks forward to its highly anticipated launch in the second half of 2025. This product is a key driver of the company's product portfolio and growth plans, and its commercial uptake will be important for supporting the revenue and margin outlook.
04—Continue